Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Nascimbeni

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Digestive Diseases (Basel, Switzerland)|July 19, 2014
Non-alcoholic fatty liver disease: diagnosis and investigationFabio Nascimbeni, Paola Loria, Vlad Ratziu
Journal of Basic and Clinical Physiology and Pharmacology|April 21, 2021
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?Giovanna Onfiani, Fabio Nascimbeni, Francesca Carubbi
Blood Cells, Molecules & Diseases|November 15, 2016
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher diseaseFabio Nascimbeni, Annalisa Dalla Salda, Francesca Carubbi
Hormone Molecular Biology and Clinical Investigation|October 28, 2018
Hypothyroidism and nonalcoholic fatty liver disease - a chance association?Simonetta Lugari, Alessandro Mantovani, Fabio Nascimbeni, et al.
Postgraduate Medicine|November 12, 2014
Drugs and acute porphyrias: reasons for a hazardous relationshipGiulia Roveri, Fabio Nascimbeni, Emilio Rocchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 20, 2016
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatmentStefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, et al.
Journal of Hepatology|November 11, 2017
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, et al.
Future Medicinal Chemistry|September 21, 2019
Extra-hepatic manifestations and complications of nonalcoholic fatty liver diseaseStefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, et al.
Internal and Emergency Medicine|January 5, 2021
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugsAlessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, et al.
Expert Review of Gastroenterology & Hepatology|May 21, 2019
A critical appraisal of the use of ultrasound in hepatic steatosisStefano Ballestri, Fabio Nascimbeni, Simonetta Lugari, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Digestive Diseases (Basel, Switzerland)|July 19, 2014
Non-alcoholic fatty liver disease: diagnosis and investigationFabio Nascimbeni, Paola Loria, Vlad Ratziu
Journal of Basic and Clinical Physiology and Pharmacology|April 21, 2021
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?Giovanna Onfiani, Fabio Nascimbeni, Francesca Carubbi
Blood Cells, Molecules & Diseases|November 15, 2016
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher diseaseFabio Nascimbeni, Annalisa Dalla Salda, Francesca Carubbi
Hormone Molecular Biology and Clinical Investigation|October 28, 2018
Hypothyroidism and nonalcoholic fatty liver disease - a chance association?Simonetta Lugari, Alessandro Mantovani, Fabio Nascimbeni, et al.
Postgraduate Medicine|November 12, 2014
Drugs and acute porphyrias: reasons for a hazardous relationshipGiulia Roveri, Fabio Nascimbeni, Emilio Rocchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 20, 2016
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatmentStefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, et al.
Journal of Hepatology|November 11, 2017
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, et al.
Future Medicinal Chemistry|September 21, 2019
Extra-hepatic manifestations and complications of nonalcoholic fatty liver diseaseStefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, et al.
Internal and Emergency Medicine|January 5, 2021
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugsAlessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, et al.
Expert Review of Gastroenterology & Hepatology|May 21, 2019
A critical appraisal of the use of ultrasound in hepatic steatosisStefano Ballestri, Fabio Nascimbeni, Simonetta Lugari, et al.
Pageof 5